73 results about "Vasodilating Agent" patented technology

A method for treating congestive heart failure (CHF) has been developed that restores kidney renal functions by artificial vasodilation of at least one kidney. A vasodilator drug is locally delivered to the kidney via a kidney perfusion catheter. The drug can be mixed with the patient's blood, saline or other suitable solvent and the mixture directly applied to the kidney through the catheter. The restoration of kidney function assists the heart by removing excess fluid, urine and toxin from the patient, and by normalizing the patient's renin-angiotensin system and other neurohormonal substances. The method is applicable to treat chronic and acute CHF.

The present invention includes 1) a novel formulation for the treatment of hair loss comprising oleanolic acid (a 5α-reductase inhibitor), apigenin (a vasodilator), and biotinyl-GHK (a cell metabolism stimulant), 2) a novel additive for the treatment of hair loss comprising oleanolic acid, apigenin, biotinyl-GHK and a delivery agent, 3) a personal care, cosmetic, and/or dermopharmaceutical composition comprising oleanolic acid, apigenin, biotinyl-GHK, and at least one additional ingredient, and 4) a method for treating hair loss comprising the administration of oleanolic acid, apigenin, and biotinyl-GHK.

Each of an ultrasonic diagnostic apparatus and an image processing apparatus according to the present invention is characterized by comprising image acquisition means for acquiring image data by scanning a patient into whom an ultrasonic contrast medium has been injected, with ultrasonic beams, same-part correspondence means for bringing same parts into correspondence with each other, between a plurality of images concerning the same parts of the identical patient and acquired by the image acquisition means, arithmetic operation means for arithmetically operating image information items on changes of intensities between the plurality of images by using the intensities of those corresponding pixels of the plurality of images which have been brought into correspondence by the pixel correspondence means, and display means for displaying results operated by the arithmetic operation means. According to the construction, it is possible to provide the ultrasonic diagnostic equipment and the image processing apparatus which can compare the images before and after injection of a vasodilator drug, more accurately in contrast echo imaging.

An apparatus for temporary prevention of embolization in a human blood vessel. The apparatus comprises a body that is transformable between a radially collapsed configuration and a radially expanded configuration sized and shaped for sealing against an inner wall of the vessel to at least partially obstruct fluid flowing there through, the body having a vasodilator coating.

This invention provides methods for the localized delivery of supplemented tissue sealants, wherein the supplemented tissue sealants comprise at least one composition which is selected from one or more antibodies, analgesics, anticoagulants, anti-inflammatory compounds, antimicrobial compositions, antiproliferatives, cytokines, cytotoxins, drugs, growth factors, interferons, hormones, lipids, demineralized bone or bone morphogenetic proteins, cartilage inducing factors, oligonucleotides polymers, polysaccharides, polypeptides, protease inhibitors, vasoconstrictors or vasodilators, vitamins, minerals, stabilizers and the like. Further provided are methods of using the site-specific supplemented tissue sealants, including preparation of a biomaterial.

Herbal cosmetic skin care compositions formulated to combat conditions associated with oxidative stress are provided. The compositions contain effective amounts of one of several active agents, including an herbal agent derived from one or more of the plant species, as well as cosmetically acceptable carriers. Other agents that may be included are proteins, peptides, anti-inflammatory agents, and/or vasodilators. These cosmetic compositions find use in improving the appearance of aged or damaged skin.

A pharmaceutical composition comprising at least one of components (a) and at least one of components (b) shown in below: (a) a compound represented by the general formula (I) (wherein R1 represents a hydrogen atom or a hydroxyl group) or an acid addition salt or hydrate thereof; and (b) an ameliorant of cerebral circulation, a vasodilator, a cerebral protecting drug, an brain metabolic stimulants, an anticoagulant, an antiplatelet drug, a thrombolytic drug, an amelirant of psychiatric symptom, a antihypertensive drug, an antianginal drug, a diuretic, a cardiotonic, an antiarrhythmic drug, an antihyperlipidemic drug, an immunosuppressant, or a pharmaceutically acceptable salt (except the components shown in (a)). It is useful as a preventive or remedy for cerebrovascular disorders and cardiac diseases.

Topical drug delivery formulations with optical amounts of vasodilator. Vasodilator chemicals applied topically dilate the blood vessels in the skin tissue, which have been shown to facilitate or inhibit systemic or skin tissue deposition of drug substances. The level of stimulation and/or inhibition has been found to be dependent on the concentration and the identity of the specific vasodilator chemical(s) used as well as the drug molecule(s) to be delivered. This work teaches the need to consider specific formulation requirements when dealing with vasodilator chemicals for the creation of successful delivery vehicles in the transdermal drug delivery system. These requirements for very low concentrations of vasodilators were an unexpected and a surprise finding, in contrast to the concentrations of the vasodilators typically used to elicit an increase in skin blood flow.

The present invention relates to compositions for supplementing the diet of subjects suffering from cardiovascular or peripheral vascular disease or those at risk for such conditions. Ribose is given alone or in combination with one or a combination of vasodilators, nutrients and vitamins. Preferred vitamins include Vitamins C, B6, B12 and folic acid. Preferred nutrients include glutamine and glucose.

Novel derivatives of isosorbide mononitrate and its pharmaceutically acceptable salts, which have vasodilating activity with a reduced effect of tolerance, of the general formula (I)

in which A and B independently represent any of the groups

—ONO₂ and —Z—CO—R, wherein Z is an oxygen atom or sulphur atom and R is an alkyl C₁-C₄ group, an aryl group or an aralkyl group, eventually substituted, or the group

in which R¹ is hydrogen, or an alkyl C₁-C₄ group, an aryl group or an aralkyl group, eventually substituted, with the proviso that one of A or B is always —ONO₂, but never both of them at the same time, when Z is an sulphur atom R is an alkyl C₁-C₄ group, an aryl group or an aralkyl group, eventually substituted, and when Z is an oxygen atom R is the group

The invention is directed to a method of administering hydrogen sulfide (H₂S) slowly and sustainably to an individual in need thereof comprising administering an effective amount of a compound represented by the following structural formula:

or a pharmaceutically acceptable salt thereof.

The invention discloses a method for calculating contrast blood flow reserve fraction based on contrast images. The method comprises the following steps: measuring pressure Pa of a coronary artery port of a heart through a blood pressure sensor; acquiring two-dimensional pipe diameter and length of a blood vessel through the contrast images, generating a three-dimensional blood vessel grid model through two contrast images with included angles of 30 degrees or more, and acquiring the three-dimensional pipe diameter and length of the blood vessel; measuring time taken by blood containing contrast agents moving from a starting point to an ending point of a specified blood vessel, and calculating blood flow velocity V<1> according to the time and the three-dimensional length of the blood vessel; and taking the blood flow velocity V<1> as a coronary artery inlet flow velocity to calculate pressure drop delta P<1> from a coronary artery inlet to a coronary artery stenosis distal end, calculating average pressure P<d1> in the coronary artery stenosis distal end through a formula of P<d1>=Pa-delta P<1>, and calculating the contrast blood flow reserve fraction through a formula of cFFR=P<d1>/Pa. Therefore, cFFR and resuming Pd/Pa can be obtained by conventional contrast images without use of vasodilators.

A freeze-dry powder injection of lactic acid milrinone used for injecting and the preparation method of the injection belong to the medical technical field. The specification of the injection is 1 to 200mg (on the milrinone basis) of the lactic acid milrinone, which can be 5mg, 10mg, 20mg or 100mg etc., wherein one kind or more one kinds is of mannitol, low-molecular dextran, cyclodextrin, soluble starch, glucide matter, sodium chloride, benzoic acid, cellulose matter or water are selected as a carrier which is acceptable for the drug. The invention also relates to the method of preparing the freeze-dry powder injection of lactic acid milrinone, and the method includes the steps of preparing liquid medicine, removing pyrogen, removing bacterium, filling into a tank, freeze-drying etc., and white or nearly white loose block-shaped matter or powder of the product is obtained. The freeze-dry powder injection of the invention has good dissolubility, high biological utilization degree and good stability and ensures that the clinical use is safer and more convenient and can be used for vein dripping; the freeze-dry powder injection of the invention is applicable to the acute heart failure, the chronic heart failure, the intractable heart failure and the congestive heart failure which are caused by various reasons and have no effect or bad effect by the treatments of a digitalis, a diuretic and a vasodilator.

A method for causing a permanent increase in the length and girth of a male subject's penis, the method comprising treatment comprising the step of (a) administering to the male an effective amount of a vasodilator selected from the group consisting of a vasodilator per se and compositions thereof comprising a pharmaceutically-acceptable diluent or carrier, to induce a cumulative prolonged engorgement of the subject's penis; and (b) repeating step (a) as necessary to cause the increase during the treatment. A potentiator which enhances the effect of the vasodilator may also be used.

A method and a device are disclosed for transdermal delivery to an animal or human of biological cargo-laden nanoparticles. The particles may include multimodal optical molecular imaging probes. The particles may be delivered by providing them in a form that can be absorbed through the skin and applying them to the skin of an animal or human. The application may be accomplished using biological cargo-laden nanoparticles in a device attachable to the skin. The device may be attached directly to the skin by a device containing a vasodilating agent or agents, or micro needles, or multi-layer time release material. The biological cargo-laden nanoparticles may comprise drugs, vaccines, bio-pharmaceuticals, imaging contrast agents, multimodal imaging contrast agents, biomolecules, or anti-infectives. The device may include a first plurality of different types of biological cargo-laden nanoparticles located in a corresponding second plurality of separate time release layers.

A method for determining and demonstrating the role of vasodilator chemical agents in the development and practice of transdermal drug delivery systems. Vasodilator chemicals applied topically dilate the blood vessels in the skin tissue, which have been shown to facilitate or inhibit systemic or skin tissue deposition of drug substances. The level of stimulation and/or inhibition has been found to be dependent on the concentration and the identity of the specific vasodilator chemical(s) used as well as the drug molecule(s) to be delivered. This work teaches the need to consider specific formulation requirements when dealing with vasodilator chemicals for the creation of successful delivery vehicles in the transdermal drug delivery system. These requirements for very low concentrations of vasodilators were an unexpected and a surprise finding, in contrast to the concentrations of the vasodilators typically used to elicit an increase in skin blood flow.

The invention provides vasodilating medication as means for lowering fever when administered to humans in need of such treatment. In particular, the use of B3 vitamin substances and Nitric Oxide-donor ingredients in compositions intended for use in reducing fever is introduced. The core composition substances can be used effectively on their own. Yet, in combination with anti-pyretic substances such as Aspirin, Acetaminophen, and Ibuprofen, the present invention enables the use of reduced dosage of composing substances for achievement of desired fever reduction effect. In addition, an optional addition of sweat inducing plant extracts in any of the noted compositions leads to a synergistic effect of reducing fever by increase of both skin blood flow and perspiration.